Navigation Links
Study Results Show Investigational Drug, Prasugrel, Cuts Risk of Stent-Related Clots by More than Half Versus Clopidogrel
Date:3/29/2008

cent vs. 11.1 percent, p=0.019). Fatal stent thrombosis occurred in 18 (0.28 percent) patients treated with prasugrel and 29 (0.46 percent) patients treated with clopidogrel (p=0.10). Of note, of the 210 patients with stent thrombosis, 89 percent either died or had a myocardial infarction associated with the event.

The rate of major bleeding was higher in all patients receiving a stent treated with prasugrel vs. clopidogrel (2.4 percent vs. 1.9 percent, p=0.06). Major bleeding in both DES and BMS prasugrel-treated groups when compared to clopidogrel-treated patients was 3 percent vs. 2 percent (p=0.34 DES) and 2 percent vs. 2 percent (p=0.09 BMS).

In addition to a reduction in the primary endpoint (CV death, non-fatal heart attack, or non-fatal stroke), a significantly lower rate of the composite endpoint of cardiovascular death, heart attack or urgent target vessel revascularization (UTVR) was observed with prasugrel vs. clopidogrel for both bare metal stents (10 percent vs. 12 percent, p=0.009) and for drug- eluting stents (9 percent vs. 11 percent, p=0.004). A significant reduction was also seen in heart attack alone (8 percent vs. 10 percent, p=0.003, BMS and 7 percent vs. 9 percent, p=.006, DES). In DES-implanted patients, regardless of those receiving only sirolimus-eluting or paclitaxel-eluting stents, there was a similar magnitude of event reduction with prasugrel compared to clopidogrel.

For the entire cohort, sub-acute stent thrombosis (24 hours to 30 days) was 0.36 percent in prasugrel-treated patients vs. 1.19 percent in clopidogrel-treated patients (p<0.0001). DES-implanted patients had lower rates of stent thrombosis compared to BMS-implanted patients, and prasugrel was shown to significantly reduce stent thrombosis in DES-implanted patients within the first three days compared to clopidogrel (0.14 percent vs. 0.63 percent, p=0.003) as well as for thromboses that occurred >30 days following the DES implantation (0.42 percent vs. 0.
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Trubion Initiates Phase 1/2 Study of TRU-016 in CLL, Announces Next-Generation Product Candidate for RA and Provides Product Pipeline Update
2. St. Jude Study Offers New Hope for Children With Kidney Tumors Deemed Inoperable
3. Sangart Completes Enrollment in Phase III Study of Its Novel Blood Substitute Hemospan
4. Sangamo BioSciences and Sigma-Aldrich Announce Publication of Study Demonstrating Zinc Finger Technology for Rapid Generation of Knock-Out Cell Lines
5. International ACTEMRA Rheumatoid Arthritis Study Highlighted in The Lancet
6. IDM Pharma Announces Availability of Mifamurtide (L-MTP-PE) Through Compassionate Access Study
7. PLC Systems Receives FDA Approval to Commence Pivotal Study Of RenalGuard(TM) In the U.S.
8. Alexion Completes Enrollment in AEGIS Registration Study of Soliris(R) (eculizumab) in Patients with PNH in Japan
9. New Study Reports That Physical Therapy Treatment Resolves Symptoms of Urinary Incontinence in Women
10. Emisphere Announces Second Study Demonstrating Dramatic Increases in Absorption of Oral B12 Using eligen(R) Technology at Lower Doses
11. Recent Data Study Suggests Cortisol Could Help Alleviate Suffering for Those With Chronic Fatigue Syndrome and Fibromyalgia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... 29, 2014 According to ... & Services (Equipment, Reagent, Primer, Probe, Custom Oligos), ... QPCR, Gene Synthesis, NGS, DNA, RNAi) - Global ... Oligonucleotide Synthesis Market is expected to reach $1,712.1 ... growing at a CAGR of 9.8% from 2014 ...
(Date:8/29/2014)... , Aug. 29, 2014 Research ... "Global Multiple Sclerosis Drugs Market 2014-2018" report ... a chronic, inflammatory medical condition that results in demyelination, ... because of an abnormal response by the immune system, ... It is a potentially debilitating disease in which the ...
(Date:8/29/2014)... VANCOUVER, British Columbia and MENLO ... -- DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar" ... 2014 fiscal year-end financial statements.  The Company recently changed ... to facilitate an application to list its common stock ... possible. DelMar,s financial statements as filed with ...
Breaking Medicine Technology:Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 2Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 3Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 4Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 2Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 3DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 2DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 3DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 4DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 5
(Date:9/1/2014)... More than 200 Lipitor lawsuit ( http://www.thelipitorlawsuit.com/ ... that continues to progress in the U.S. District Court, ... , A federal Case List published on August 15th ... medication by plaintiffs who developed Type 2 diabetes allegedly ... failed to adequately warn patients and their doctors about ...
(Date:9/1/2014)... HealthDay Reporter FRIDAY, Aug. 29, 2014 (HealthDay ... American aid workers successfully cured a group of monkeys infected ... The drug, ZMapp, prompted recovery in all 18 monkeys who ... five days after infection. ZMapp even cured monkeys with ... away from death, said study senior author Gary Kobinger, chief ...
(Date:9/1/2014)... (PRWEB) September 01, 2014 As well ... training, Derek is currently pursuing counselor certification in Louisiana. ... advance through the CPI training program as well as ... I have grown both personally and professionally. I ... I am competently able to do so. As ...
(Date:9/1/2014)... York (PRWEB) September 01, 2014 ... retrieve, organize and analyze biological and genetic data. ... the activity of developing software tools to generate ... to be confused with biological computation. While bioinformatics ... understanding of biology can its related concepts, biological ...
(Date:9/1/2014)... Secaucus, NJ (PRWEB) September 01, 2014 Registration ... For The Warriors® 5K and 1-Mile Race to be held ... at The Plaza Court Yard at Harmon Meadow in Secaucus, ... For The Warriors®, a national nonprofit dedicated to restoring a ... for our service members and our military families. , General ...
Breaking Medicine News(10 mins):Health News:South Carolina Litigation Adds 200 Lipitor Lawsuits in a Month, as Plaintiffs File Suits Alleging New-Onset Diabetes, Bernstein Liebhard LLP Reports 2Health News:South Carolina Litigation Adds 200 Lipitor Lawsuits in a Month, as Plaintiffs File Suits Alleging New-Onset Diabetes, Bernstein Liebhard LLP Reports 3Health News:Monkey Trial Supports Ebola Drug That May Have Helped 2 Stricken Americans 2Health News:Monkey Trial Supports Ebola Drug That May Have Helped 2 Stricken Americans 3Health News:Narconon Louisiana Announces New Certifications For Staff 2Health News:Bioinformatics Market: A fusion of Computers and Biological Data 2Health News:Bioinformatics Market: A fusion of Computers and Biological Data 3Health News:Bioinformatics Market: A fusion of Computers and Biological Data 4Health News:Hope For The Warriors New Jersey Run to Honor Wounded and Families of the Fallen 2
... For the first time, universal standards to guide ... labels to reflect how patients read and understand medication ... labels can vary significantly from pharmacy to pharmacy, even ... the safe use of medications. The new standards, developed ...
... hills . . . They might get a pedestrian ... someone in an electric wheelchair, they could mean terrain ... To address this problem, researchers at the Florida A&M ... technology that will enable electric-powered wheelchairs to detect hazardous ...
... into a collaborative agreement with Veridex LLC to establish ... cell (CTC) technologies. The overall goal of the agreement ... and characterizing CTCs, solid tumor cells found at extremely ... key to noninvasive characterization of cancer and potentially to ...
... and other developing countries is seasonal, linked to farm ... according to an international team of researchers from Uganda ... approach to this problem is prevention. "Hydrocephalus in infants ... Steven Schiff, the Brush Chair professor of engineering and ...
... a clear association of tuberculosis with lung cancer remains ... January issue of the Journal of Thoracic Oncology ... among people with tuberculosis. Researchers at China Medical ... patients covered under the country,s National Health Insurance (NHI) ...
... Dec. 31 (HealthDay News) -- Two to three times more ... and New Year,s than over comparable periods of time during ... on Alcohol Abuse and Alcoholism. The agency also noted ... an impaired driver, compared to 28 percent for the rest ...
Cached Medicine News:Health News:Universal standards proposed for prescription container labels to help reduce medication misuse 2Health News:Universal standards proposed for prescription container labels to help reduce medication misuse 3Health News:FSU researchers helping electric-wheelchair users move more easily 2Health News:FSU researchers helping electric-wheelchair users move more easily 3Health News:Mass. General enters collaboration to develop new approach to capturing circulating tumor cells 2Health News:Infant hydrocephalus, seasonal and linked to farm animals in Uganda 2Health News:Infant hydrocephalus, seasonal and linked to farm animals in Uganda 3Health News:Infant hydrocephalus, seasonal and linked to farm animals in Uganda 4Health News:Study finds evidence of increased lung cancer risk among tuberculosis patients 2Health News:Holiday Drinking Raises Death Toll on U.S. Roads, Experts Warn 2
... stereopsis from 800 to 40 ... young as 2 years of ... from left to right., ,Randot ... Book #1: 200 & 100 ...
... The Standard for Stereo Depth Perception. ... 1200 sec or arc) and Fine ... Circle Test (800 to 40 sec ... (400 to 100 sec of arc), ...
The Emit Phenytoin Assay is a homogeneous enzyme immunoassay for use in the quantitative analysis of phenytoin in human serum or plasma....
The Emit 2000 Phenytoin Assay is a homogeneous enzyme immunoassay for use in the quantitative analysis of phenytoin in human serum or plasma. Kits are conveniently packaged in Olympus Reagent Cartrid...
Medicine Products: